Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers June 27, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - June 27, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/20/17 - Global Needle-Free Drug Delivery Market 2017-2021: Endo Pharmaceuticals, Antares Pharma, Inovio Pharmaceuticals, Valeritas, PharmaJet
The market is divided into the following segments based on geography:- Americas- APAC- EMEA. Key vendors- Endo Pharmaceuticals- Antares Pharma- Inovio Pharmaceuticals- Valeritas- PharmaJet. Other prominent vendors- 3 M- Akra Dermojet- Consort Medical- CROSSJECT- Injex Pharma- PenJet Corporation- Zosano- DAntonio Consultants International- European
6/19/17 - "High-Definition Particle Detection during Centrifugation" in Patent Application Approval Process (USPTO 20170153431)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Nguyen, Hoang Thanh; Noolandi, Jaan; Schultheis, Robert James, filed on November 28, 2016, was made available online on June 8, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application ha
6/19/17 - Acceleron Pharma Inc. Files SEC Form 8-K, Current Report (Jun. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on June 6, 2017. The SEC file number is 0001280600-17-000033.. A U.S. Securities and Exchange Commission filing is a
6/19/17 - Acelrx Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 5, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on June 5, 2017. The SEC file number is 0001437749-17-010591.. A U.S. Securities and Exchange Commission filin
6/19/17 - Acelrx Pharmaceuticals Inc. Files SEC Form S-3, Registration Statement Under Securities Act of 1933 (Jun. 5, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on June 5, 2017. The SEC file number is 0001437749-17-010647.. A U.S. Securities and Exchange Commission filin
6/19/17 - Acorda Presenting New Tozadenant Data at 2017 MDS Congress
By a News Reporter-Staff News Editor at Pharma Business Week Acorda Therapeutics, Inc. is presenting new data from clinical and preclinical studies of tozadenant at the 2017 International Congress of Parkinson's Disease and Movement Disorders, being held in Vancouver, British Columbia from June 4-8, 2017. "OFF is cited by people with Parkinson's
6/19/17 - Active Implants SUN Clinical Trial for Persistent Knee Pain Now Underway in San Diego
By a News Reporter-Staff News Editor at Clinical Trials Week Active Implants, a company that develops orthopedic implant solutions, announced that the company's SUN trial is now underway in San Diego. Scott A. Hacker at Grossmont Orthopaedic Medical Group is the only physician in San Diego County- and the center is one of just 10 sites nationwide
6/19/17 - Adamas Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 2, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on June 2, 2017. The SEC file number is 0001209191-17-037336.. A U.S. Securities and Exchange Commission filin
6/19/17 - Adamas Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 1, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on June 1, 2017. The SEC file number is 0001628280-17-006145.. A U.S. Securities and Exchange Commission filin
6/19/17 - Adamas Pharmaceuticals Inc. Files SEC Form SC 13G, Statement of Acquisition of Beneficial Ownership By Individuals (Jun. 1, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on June 1, 2017. The SEC file number is 0000919574-17-004645.. A U.S. Securities and Exchange Commission filin
6/19/17 - Aerie Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 1, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aerie Pharmaceuticals Inc. was posted on June 1, 2017. The SEC file number is 0001193125-17-191276.. A U.S. Securities and Exchange Commission filing
6/19/17 - Aerie Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 5, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aerie Pharmaceuticals Inc. was posted on June 5, 2017. The SEC file number is 0001193125-17-193621.. A U.S. Securities and Exchange Commission filing
6/19/17 - Agency Information Collection Activities; Proposed Collection; Comment Request; Disclosures of Descriptive Presentations in Professional Oncology...
SUMMARY: The Food and Drug Administration is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information and to allow 60 days for publ
6/19/17 - Agency Information Collection Activities; Proposed Collection; Comment Request; Orphan Drugs; Common European Medicines Agency/Food and Drug...
SUMMARY: The Food and Drug Administration is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995, Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed...
6/19/17 - Agios Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (Jun. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agios Pharmaceuticals Inc. was posted on June 6, 2017. The SEC file number is 0001193125-17-195994.. A U.S. Securities and Exchange Commission filing
6/19/17 - Akebia Therapeutics, Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (Jun. 1, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Akebia Therapeutics, Inc. was posted on June 1, 2017. The SEC file number is 0001562180-17-002107.. A U.S. Securities and Exchange Commission filing
6/19/17 - Akebia Therapeutics, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 2, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Akebia Therapeutics, Inc. was posted on June 2, 2017. The SEC file number is 0001562180-17-002141.. A U.S. Securities and Exchange Commission filing
6/19/17 - Alectinib halts lung cancer growth more than a year longer than crizotinib
By a News Reporter-Staff News Editor at Clinical Trials Week ASCO Perspective. The study will be featured in a press briefing today and presented at the 2017 American Society of Clinical Oncology Annual Meeting. "This is the first global study to compare alectinib with crizotinib in ALK-positive lung cancer and establishes alectinib as the new s
6/19/17 - All Vaccine Market Report 2017 | Manufacturers, Countries, Type and Application, Forecast to 2022
All Vaccine MarketReport offered by DecisionDatabases.com gives a market overview of the All Vaccine industry which covers product scope, market revenue, opportunities, growth rate, sales volumes and figures. The report also explores the wo...
6/19/17 - Allergan to Present New Data on Chronic Migraine at the American Headache Society Meeting in Boston
By a News Reporter-Staff News Editor at Pharma Business Week Allergan plc announced that data on Chronic Migraine and the Company's Chronic Migraine treatment will be featured in eight presentations at the upcoming 59th American Headache Society Annual Scientific Meeting taking place June 8-11, 2017 in Boston. Allergan, a leader in the Chronic Mi
6/19/17 - Allergan's Trademark Application for "OCUFEN" Filed
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a trademark application has been made for "OCUFEN" by Susan J. Hinchey, representing Allergan. This application was made available to the public on June 07, 2017. The owner/registrar information for th
6/19/17 - Alnylam CEO, John Maraganore, Named BIO Chair for 2017-2018 Term
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced that Chief Executive Officer John Maraganore, Ph.D., has been elected as the Chair of the Biotechnology Innovation Organization Board of Directors for the 2017-2018 term. BIO has long supported the innovative, transformative work of the biotech community, and i
6/19/17 - Alnylam Pharmaceuticals, Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alnylam Pharmaceuticals, Inc. was posted on June 6, 2017. The SEC file number is 0001553878-17-000018.. A U.S. Securities and Exchange Commission fil
6/19/17 - Alnylam Pharmaceuticals, Inc. Files SEC Form 8-K, Current Report (Jun. 6, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Alnylam Pharmaceuticals, Inc. was posted on June 6, 2017. The SEC file number is 0001193125-17-195385.. A U.S. Securities and Exchange Commission fil
6/19/17 - Amag Pharmaceuticals Inc. Files SEC Form 4, Statement of Changes in Beneficial Ownership of Securities (Jun. 5, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Amag Pharmaceuticals Inc. was posted on June 5, 2017. The SEC file number is 0001179110-17-008492.. A U.S. Securities and Exchange Commission filing
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415